Literature DB >> 18217931

Molecular cloning, overexpression and biochemical characterization of hypothetical beta-lactamases of Mycobacterium tuberculosis H37Rv.

K M Nampoothiri1, R Rubex, A K Patel, S S Narayanan, S Krishna, S M Das, A Pandey.   

Abstract

AIM: Molecular cloning, overexpression and biochemical characterization of the genes from the Mycobacterium tuberculosis H37Rv genome having hypothetical beta-lactamases activity. METHODS AND
RESULTS: Analysis of the M. tuberculosis H37Rv genome revealed that Rv2068c, Rv0406c and Rv3677c gene products were predicted to exhibit beta-lactamases activity. All the three genes were cloned in pET28a vector and overexpressed in C41 (DE3) Escherichia coli cells. The His-tagged recombinant proteins were confirmed by immunoblotting and were shown to have beta-lactamase activity by the hydrolysis of nitrocefin and other beta-lactams. Catalytic parameters for all the recombinant proteins were derived followed by the enzyme inhibition studies. Antibiotic susceptibility studies using the recombinant strains showed an increased resistance against different classes of beta-lactam antibiotics.
CONCLUSION: The study revealed the possibility of more than one gene in M. tuberculosis, encoding proteins having beta-lactamase or beta-lactamase-like activity, giving wide spectrum of resistance against beta-lactams. SIGNIFICANCE AND IMPACT OF THE STUDY: Systematic study of hypothetical beta-lactamases of M. tuberculosis and related species and their correlation with beta-lactam and inhibitor susceptibility profile might be useful in developing new antibiotic regime for the treatment of tuberculosis caused by multiple drug resistant (MDR) strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18217931     DOI: 10.1111/j.1365-2672.2007.03721.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  11 in total

Review 1.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

2.  A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Authors:  Daigo Inoyama; Divya Awasthi; Glenn C Capodagli; Kholiswa Tsotetsi; Paridhi Sukheja; Matthew Zimmerman; Shao-Gang Li; Ravindra Jadhav; Riccardo Russo; Xin Wang; Courtney Grady; Todd Richmann; Riju Shrestha; Liping Li; Yong-Mo Ahn; Hsin Pin Ho Liang; Marizel Mina; Steven Park; David S Perlin; Nancy Connell; Véronique Dartois; David Alland; Matthew B Neiditch; Pradeep Kumar; Joel S Freundlich
Journal:  Cell Chem Biol       Date:  2020-03-19       Impact factor: 8.116

3.  In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.

Authors:  Suresh Solapure; Neela Dinesh; Radha Shandil; Vasanthi Ramachandran; Sreevalli Sharma; Deepa Bhattacharjee; Samit Ganguly; Jitendar Reddy; Vijaykamal Ahuja; Vijender Panduga; Manish Parab; K G Vishwas; Naveen Kumar; Meenakshi Balganesh; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

Review 4.  Molecular biology of drug resistance in Mycobacterium tuberculosis.

Authors:  Tasha Smith; Kerstin A Wolff; Liem Nguyen
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 5.  Have we realized the full potential of β-lactams for treating drug-resistant TB?

Authors:  Elizabeth Story-Roller; Gyanu Lamichhane
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

6.  2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.

Authors:  Albert B Jeon; Andrés Obregón-Henao; David F Ackart; Brendan K Podell; Juan M Belardinelli; Mary Jackson; Tuan V Nguyen; Meghan S Blackledge; Roberta J Melander; Christian Melander; Benjamin K Johnson; Robert B Abramovitch; Randall J Basaraba
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

Review 7.  New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria.

Authors:  Mohammad J Nasiri; Mehri Haeili; Mona Ghazi; Hossein Goudarzi; Ali Pormohammad; Abbas A Imani Fooladi; Mohammad M Feizabadi
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

8.  Ample glycosylation in membrane and cell envelope proteins may explain the phenotypic diversity and virulence in the Mycobacterium tuberculosis complex.

Authors:  Alemayehu Godana Birhanu; Solomon Abebe Yimer; Shewit Kalayou; Tahira Riaz; Ephrem Debebe Zegeye; Carol Holm-Hansen; Gunnstein Norheim; Abraham Aseffa; Markos Abebe; Tone Tønjum
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

Review 9.  Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles' heel for the TB-causing pathogen.

Authors:  Arundhati Maitra; Tulika Munshi; Jess Healy; Liam T Martin; Waldemar Vollmer; Nicholas H Keep; Sanjib Bhakta
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

10.  Collateral Sensitivity to β-Lactam Drugs in Drug-Resistant Tuberculosis Is Driven by the Transcriptional Wiring of BlaI Operon Genes.

Authors:  A S Trigos; B W Goudey; J Bedő; T C Conway; N G Faux; K L Wyres
Journal:  mSphere       Date:  2021-05-28       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.